Aurinia Pharmaceuticals Inc.

Listed Company

AUPHCIK 0001600620NasdaqLarge AcceleratedPharmaceutical PreparationsCAFY ends Dec 31

Period

FY 2025

Revenue

$283.06M

Net Income

$287.20M

Total Assets

$751.59M

Equity

$581.33M

Shares Out

128.60M

Op. Cash Flow

$135.66M

AUPH$15.97+75.88% · past yearDBEQ Basic

Daily closing prices

Business

Aurinia Pharmaceuticals is a biopharmaceutical company developing therapies for autoimmune diseases with high unmet medical needs. The company markets LUPKYNIS (voclosporin), the first FDA-approved oral therapy for adult patients with active lupus nephritis, and generates the majority of its product revenue from LUPKYNIS sales. Aurinia also develops aritinercept, a dual BAFF/APRIL inhibitor for autoimmune diseases. The company sells LUPKYNIS directly in the U.S. and supplies it to Otsuka Pharmaceutical for commercialization in Japan, the European Union, the United Kingdom, and Switzerland.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	283	235	176	134	46
Cost of revenue	33	28	14	6	1
Selling, general and administrative	102	172	195	196	174
Research and development	33	21	50	45	51
Restructuring	2	23	0	0	—
Other expense (income), net	10	−4	8	−2	574,000
Total operating expenses	178	240	267	246	226
Income (loss) from operations	105	−5	−92	−111	−181
Interest income	14	17	17	5	—
Interest expense	−4	−5	−3	0	—
Net income (loss) before income taxes	114	7	−77	−106	−180
Income tax (benefit) expense	−173	2	551,000	2	760,000
Net income (loss)	287	6	−78	−108	−181
Unrealized gain on available-for-sale securities	48,000	83,000	331,000	−209,000	−47,000
Comprehensive income (loss)	287	6	−78	−108	−181
Basic (in usd per share)	2.14	0.04	−0.54	−0.76	−1.4
Diluted (in usd per share)	2.07	0.04	−0.54	−0.76	−1.4
Basic (in shares)	134	143	143	142	129
Diluted (in shares)	139	146	143	142	129

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash, cash equivalents and restricted cash	80	83	49	94	232
Short-term investments	318	275	302	295	234
Accounts receivable, net	41	37	24	14	15
Inventory	46	39	40	25	19
Prepaid expenses and deposits	6	11	9	—	—
Other current assets	1	1	1	1	796,000
Total current assets	492	447	425	443	513
Deferred tax assets, net	176	0	—	—	—
Finance right-of-use lease assets	74	92	109	0	—
Intangible assets, net	4	4	5	6	8
Operating right-of-use lease assets	4	4	4	5	5
Property and equipment, net	2	3	3	4	4
Other noncurrent assets	93,000	823,000	2	13	12
Total assets	752	551	548	471	543
Accounts payable	3	5	4	—	—
Accrued expenses	67	65	50	—	—
Finance lease liabilities, current portion	17	14	15	0	—
Deferred revenue	4	11	5	3	190,000
Operating lease liabilities, current portion	1	1	989,000	936,000	1
Other current liabilities	2	2	2	2	4
Total current liabilities	94	98	77	46	41
Finance lease liabilities, less current portion	52	59	75	0	—
Deferred revenue, less current portion	13	2	—	—	—
Deferred compensation and other noncurrent liabilities	7	9	—	—	—
Operating lease liabilities, less current portion	5	6	7	7	8
Total liabilities	170	173	170	65	64
Commitments and contingencies (Note 5)	—	—	—	—	—
Common shares - no par value, Unlimited shares authorized, 132,323 and 140,883 shares issued and outstanding at December 31, 2025 and 2024, respectively	1,120	1,188	1,200	1,185	1,177
Additional paid-in capital	111	127	121	85	59
Accumulated other comprehensive loss	−599,000	−647,000	−730,000	−1	−852,000
Accumulated deficit	−649	−937	−942	−864	−756
Total shareholders' equity	581	377	378	405	479
Total liabilities and shareholders' equity	752	551	548	471	543

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Deferred income tax benefit	−176	0	0	—	—
Amortization and depreciation	19	19	12	3	3
Share-based compensation	15	32	45	32	31
Foreign exchange loss (gain) on revaluation of Monoplant finance lease liability	10	−6	6	0	—
Net amortization of premiums and discounts on investments	−10	−13	−12	−2	660,000
Non-cash write-down of inventory	0	0	916,000	4	245,000
Other, net	−200,000	788,000	−2	−2	−2,000
Accounts receivable, net	−5	−12	−11	2	−15
Inventory	−6	477,000	−16	−9	−6
Prepaid expenses and other current assets	6	−2	4	−2	−5
Other noncurrent operating assets	730,000	31,000	−16,000	−363,000	353,000
Accounts payable	−2	860,000	1	−792,000	—
Accrued expenses and other liabilities	−5	13	12	1	—
Deferred revenue	4	6	4	3	0
Operating lease liabilities	−802,000	−750,000	−673,000	−652,000	332,000
Cash flows from operating activities	136	44	−33	−80	−158
Proceeds from the sale and maturities of investments	494	585	529	464	354
Purchases of investments	−527	−546	−524	−524	−439
Upfront lease payments	0	−43,000	−12	−663,000	−12
Purchases of property, equipment and intangible assets	−252,000	−281,000	−718,000	−292,000	−303,000
Cash flows from investing activities	−33	39	−7	−61	−104
Repurchase of common shares	−98	−40	0	0	—
Principal portion of finance lease payments	−13	−12	−10	0	0
Proceeds from issuance of common shares from exercise of stock options and vesting of RSUs and performance awards	14	8	5	2	24
Proceeds from issuance of common shares under ESPP	756,000	1	2	2	197
Taxes paid related to net settlement of exercises of stock options and vesting of RSUs and performance awards	−10	−6	−2	−1	—
Cash flows from financing activities	−106	−49	−5	2	221
Net (decrease) increase in cash, cash equivalents and restricted cash	−3	35	−45	−138	−40
Finance lease liability arising from obtaining right-of-use assets	0	0	94	0	—
Cash paid for income taxes	−3	−2	−496,000	−2	—
Taxes withheld related to vesting of performance awards	4	0	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Aurinia Pharmaceuticals Inc.'s CIK number?

Aurinia Pharmaceuticals Inc.'s SEC CIK number is 0001600620 (1600620). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Aurinia Pharmaceuticals Inc.'s SEC filings?

All of Aurinia Pharmaceuticals Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Aurinia Pharmaceuticals Inc. last report earnings?

Aurinia Pharmaceuticals Inc. (AUPH) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001600620-26-000048). This is Aurinia Pharmaceuticals Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Aurinia Pharmaceuticals Inc.'s most recent earnings 8-K?

Aurinia Pharmaceuticals Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001600620-26-000048. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Aurinia Pharmaceuticals Inc.'s latest earnings 8-K →
Look up any company's CIK number →